NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Clinical Trials
14 trialsNCT03922880 2025-05-15
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03472586 2025-04-24
Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver
Thomas Jefferson University
Phase 2 Completed
NCT01355120 2025-04-09
DeCOG
University Hospital, Essen
Phase 2 Completed
NCT04463368 2025-03-28
SCANDIUM II
Vastra Gotaland Region
Phase 1 Completed
NCT05169957 2024-11-05
Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT01585194 2024-07-09
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03408587 2023-05-06
CLEVER
Viralytics
Phase 1 Completed
NCT00084656 2022-04-14
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT02626962 2022-03-22
GEM1402
Grupo Español Multidisciplinar de Melanoma
Phase 2 Completed
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT00025181 2014-05-22
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
University of Southern California
Phase 1 Completed
NCT00032045 2013-06-20
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00058279 2013-06-20
Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1/2 Completed